Medis customers in five major European countries have launched Valsartan and Valsartan HCT tablets immediately after the patents expired. Valsartan and Valsartan HTC were launched from Medis manufacturing sites in Malta and Dupnitza Bulgaria. Valsartan is the generic equivalent of the Diovan® from Novartis brand product.
It is primarily used for the treatment of high blood pressure, alone or in combination with other medication. Medis is launching this product in two versions, as a mono product and in combination with Hydrochlorothiazide (HCT). Medis has already launched Valsartan to its customers in Hungary and Spain where relevant patents expired earlier this year.